Abstract
High altitude sickness (HAS) has been one of the important environmental challenges occurring as a result of the failure of the physiological acclimatization to acute hypobaric hypoxia. The prime bodily retort to hypoxia and adaptation linked to HAS comprises hyperventilation, increased systemic blood pressure together with tachycardia (increased heart rate) and increased hemoglobin concentration. These collective retorts enhance the supply of oxygen to the cells by means of alterations in the respiratory, cardiovascular, and hematologic system, thereby boosting the cellular oxygen uptake together with consumption mechanisms. Additionally, in majority of the cases, these bodily responses may not be sufficient, as a result the mount to high elevations and the associated hypoxia culminate in complex medical condition. Diverse strategies for preventing HAS can be employed categorized mainly into pharmacological and non-pharmacological and miscellaneous. Pharmacological interventions comprise drugs like acetazolamide or dexamethasone which have been found to work effectively but also linked with adverse physical secondary effects. Non-pharmacological and miscellaneous interventions are those which are not founded on the administration of drugs and can be categorized into two sets: pre-acclimatization and supplements. Pre-acclimatization and additional methods founded on pressure comprise the employment of hypobaric air breathing to sham higher elevations, positive end-expiratory pressure, and remote ischemic preconditioning. In addition, non-drug approaches, herbs, and natural supplements have been also tested and found to be promising in combating this challenge. Supplements may contain herbal extracts (like Ginkgo biloba, Rhodiola species, and Coca leaf products), mineral elements (like iron, magnesium), antacids, and hormonal agents (like medroxyprogesterone and erythropoietin). Hypoxia is well known for causing prooxidant/antioxidant disturbances in the cell, thereby resulting in oxidative stress. The key mechanisms through which hypoxia-induced reactive oxygen species (ROS) overgeneration takes place are increased catecholamine manufacture, mitochondrial redox potential diminution together with the stimulation of xanthine oxidase pathway. The scientific observations of a raised risk of ROS and free radical mediated oxidative insult at higher elevation have shown the way to the researchers to suggest nutritional antioxidant interventions such as ascorbic acid, beta-carotene, vitamin E, selenium, alpha-lipoic acid, etc. present in fruits and vegetables and herbal supplements rich in antioxidants like Ginkgo biloba, which may be advantageous in combating the problem of HAS. Several antioxidants and their concoction have been tested and have shown mixed results in relation to the effectiveness of antioxidants in averting HAS. Despite the bulk of scientific investigations exploring the beneficial effects as well as the effectiveness of various antioxidants against HAS in different experimental models, the present state of evidence is unable to substantiate or repudiate the use of any antioxidant or a concoction of antioxidant as a definite prophylactic agent. Additionally, an inadequate number of investigations support the effectiveness of antioxidant supplements at higher elevations in easing the difficulty of HAS. Furthermore, there is a dearth of standardized studies in this regard. The variations in the current investigations with regard to experimental design considerations like altitude reached, rate of ascension, degree of pre-acclimatization; antioxidant employed, purity and quality of the antioxidant, the timing, duration, pretreatment, and dosage administered; individual susceptibility, small sample size, etc. cloud the understanding with respect to their efficacy in bringing out the desirable effects. Another challenge in this regard is to identify the appropriate dosage, timing, or combination of antioxidants which will regulate the induced oxidative stress without any deleterious effects on the body and therefore help the body to ease out the symptoms of HAS. Therefore, given the undesirable side effects associated with pharmacological interventions, non-pharmacological antioxidant interventions which are relatively safer and with minimal side effects need more attention in order to combat this challenge of HAS.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Armstead WM, Mirro R, Thelin OP, Shibata M, Zuckerman SL, Shanklin DR, Busija DW, Leffler CW (1992) Polyethylene glycol superoxide dismutase and catalase attenuate increased blood-brain barrier permeability after ischemia in piglets. Stroke 23:755–762
Askew EW (2002) Work at high altitude and oxidative stress: antioxidant nutrients. Toxicology 180(2):107–119. https://doi.org/10.1016/s0300-483x(02)00385-2
Bailey DM, Davies B (2001) Acute mountain sickness; prophylactic benefits of antioxidant vitamin supplementation at high altitude. High Alt Med Biol 2(1):21–29. https://doi.org/10.1089/152702901750067882
Bailey DM, Davies B, Young IS, Hullin DA, Seddon PS (2001) A potential role for free radical-mediated skeletal muscle soreness in the pathophysiology of acute mountain sickness. Aviat Space Environ Med 72(6):513–521
Baillie JK, Thompson AA, Irving JB, Bates MG, Sutherland AI, Macnee W, Maxwell SR, Webb DJ (2009) Oral antioxidant supplementation does not prevent acute mountain sickness: double blind, randomized placebo-controlled trial. QJM 102(5):341–348. https://doi.org/10.1093/qjmed/hcp026
Bärtsch P, Saltin B (2008) General introduction to altitude adaptation and mountain sickness. Scand J Med Sci Sports 18(Suppl 1):1–10. https://doi.org/10.1111/j.1600-0838.2008.00827.x
Basnyat B, Murdoch DR (2003) High-altitude illness. Lancet 361:1967–1974
Bendich A, Machlin LJ, Scandurra O, Burton GW, Wayner DDM (1986) The antioxidant role of vitamin C. Adv Free Radic Biol Med 2(2):419–444
Berg JT (2004) Ginkgo biloba extract prevents high altitude pulmonary edema in rats. High Alt Med Biol 5(4):429–434. https://doi.org/10.1089/ham.2004.5.429
Berger MM, Macholz F, Lehmann L, Dankl D, Hochreiter M, Bacher B et al (2017) Remote ischemic preconditioning does not prevent acute mountain sickness after rapid ascent to 3,450 m. J Appl Physiol 123(5):1228–1234
Burse RL, Forte VA Jr (1988) Acute mountain sickness at 4500 m is not altered by repeated eight-hour exposures to 3200-3550 m normobaric hypoxic equivalent. Aviat Space Environ Med 59(10):942–949
Burtscher M, Flatz M, Faulhaber M (2004) Prediction of susceptibility to acute mountain sickness by SaO2 values during short-term exposure to hypoxia. High Alt Med Biol 5(3):335–340. https://doi.org/10.1089/ham.2004.5.335
Chao WH, Askew EW, Roberts DE, Wood SM, Perkins JB (1999) Oxidative stress in humans during work at moderate altitude. J Nutr 129(11):2009–2012. https://doi.org/10.1093/jn/129.11.2009
Chiu T-F, Chen LL-C, Su D-H, Lo H-Y, Chen C-H, Wang S-H, Chen W-L (2013) Rhodiola crenulata extract for prevention of acute mountain sickness: a randomized, double-blind, placebo-controlled, crossover trial. BMC Complement Altern Med 13:298. https://doi.org/10.1186/1472-6882-13-298
Chow T, Browne V, Heileson HL, Wallace D, Anholm J, Green SM (2005) Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo-controlled trial. Arch Intern Med 165(3):296–301. https://doi.org/10.1001/archinte.165.3.296
Committee to Advise on Tropical Medicine and Travel (CATMAT) (2007) Statement on high-altitude illnesses. An Advisory Committee Statement (ACS). Can Commun Dis Rep 33(ACS-5):1–20
Davis C, Hackett P (2017) Advances in the prevention and treatment of high altitude illness. Emerg Med Clin North Am 35(2):241–260. https://doi.org/10.1016/j.emc.2017.01.002
Dehnert C, Bärtsch P (2010) Can patients with coronary heart disease go to high altitude? High Alt Med Biol 11(3):183–188. https://doi.org/10.1089/ham.2010.1024
Dehnert C, Böhm A, Grigoriev I, Menold E, Bärtsch P (2014) Slee** in moderate hypoxia at home for prevention of acute mountain sickness (AMS): a placebo-controlled, randomized double-blind study. Wilderness Environ Med 25(3):263–271. https://doi.org/10.1016/j.wem.2014.04.004
Du G, Willet K, Mouithys-Mickalad A, Sluse-Goffart CM, Droy-Lefaix MT, Sluse FE (1999) EGb 761 protects liver mitochondria against injury induced by in vitro anoxia/reoxygenation. Free Radic Biol Med 27(5-6):596–604. https://doi.org/10.1016/s0891-5849(99)00103-3
Dumont L, Mardirosoff C, Soto-Debeuf G, Tassonyi E (1999) Magnesium and acute mountain sickness. Aviat Space Environ Med 70(6):625
Gaillard S, Dellasanta P, Loutan L, Kayser B (2004) Awareness, prevalence, medication use, and risk factors of acute mountain sickness in tourists trekking around the Annapurnas in Nepal: a 12-year follow-up. High Alt Med Biol 5(4):410–419. https://doi.org/10.1089/ham.2004.5.410
Gertsch JH, Seto TB, Mor J, Onopa J (2002) Ginkgo biloba for the prevention of severe acute mountain sickness (AMS) starting one day before rapid ascent. High Alt Med Biol 3(1):29–37. https://doi.org/10.1089/152702902753639522
Gertsch JH, Basnyat B, Johnson EW, Onopa J, Holck PS (2004) and Prevention of High Altitude Illness Trial Research Group. Randomised, double blind, placebo controlled comparison of Ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ 328(7443):797. https://doi.org/10.1136/bmj.38043.501690.7C
Hackett PH, Yarnell PR, Hill R, Reynard K, Heit J, McCormick J (1998) High-altitude cerebral edema evaluated with magnetic resonance imaging: clinical correlation and pathophysiology. JAMA 280(22):1920–1925. https://doi.org/10.1001/jama.280.22.1920
Halliwell B (1992) Reactive oxygen species and the central nervous system. J Neurochem 59(5):1609–1623. https://doi.org/10.1111/j.1471-4159.1992.tb10990.x
Halliwell B (1994) Free radicals and antioxidants: a personal view. Nutr Rev 52(8 Pt 1):253–265. https://doi.org/10.1111/j.1753-4887.1994.tb01453.x
Halliwell B, Gutteridge JMC (1999) Free radicals in biology and medicine. Oxford University Press, Oxford
Heo K, Kang JK, Choi CM, Lee MS, Noh KW, Kim SB (2014) Prophylactic effect of erythropoietin injection to prevent acute mountain sickness: an open-label randomized controlled trial. J Korean Med Sci 29(3):416–422. https://doi.org/10.3346/jkms.2014.29.3.416
Hörl WH (2007) Iron therapy for renal anemia: how much needed, how much harmful? Pediatr Nephrol 22(4):480–489. https://doi.org/10.1007/s00467-006-0405-y
Hung SK, Perry R, Ernst E (2011) The effectiveness and efficacy of Rhodiola rosea L.: a systematic review of randomized clinical trials. Phytomedicine 18(4):235–244. https://doi.org/10.1016/j.phymed.2010.08.014
Icard P, Saumon G (1999) Alveolar sodium and liquid transport in mice. Am J Phys 277(6):L1232–L1238
Ilavazhagan G, Bansal A, Prasad D, Thomas P, Sharma SK, Kain AK, Kumar D, Selvamurthy W (2001) Effect of vitamin E supplementation on hypoxia-induced oxidative damage in male albino rats. Aviat Space Environ Med 72(10):899–903
Imai H, Kashiwazaki H, Suzuki T, Kabuto M, Himeno S, Watanabe C, Moji K, Kim SW, Rivera JO, Takemoto T (1995) Selenium levels and glutathione peroxidase activities in blood in an Andean high-altitude population. J Nutr Sci Vitaminol (Tokyo) 41(3):349–361. https://doi.org/10.3177/jnsv.41.349
Imray C, Wright A, Subudhi A, Roach R (2010) Acute mountain sickness: pathophysiology, prevention, and treatment. Prog Cardiovasc Dis 52(6):467–484. https://doi.org/10.1016/j.pcad.2010.02.003
Joanny P, Steinberg J, Robach P, Richalet JP, Gortan C, Gardette B, Jammes Y (2001) Operation Everest III (Comex‘97): the effect of simulated sever hypobaric hypoxia on lipid peroxidation and antioxidant defence systems in human blood at rest and after maximal exercise. Resuscitation 49(3):307–314. https://doi.org/10.1016/s0300-9572(00)00373-7
Ke T, Wang J, Swenson ER, Zhang X, Hu Y, Chen Y, Liu M, Zhang W, Zhao F, Shen X, Yang Q, Chen J, Luo W (2013) Effect of acetazolamide and gingko biloba on the human pulmonary vascular response to an acute altitude ascent. High Alt Med Biol 14(2):162–167. https://doi.org/10.1089/ham.2012.1099
Kehrer JP, Lund LG (1994) Cellular reducing equivalents and oxidative stress. Free Radic Biol Med 17(1):65–75. https://doi.org/10.1016/0891-5849(94)90008-6
Kleijnen J, Knipschild P (1992) Ginkgo biloba. Lancet 340(8828):1136–1139. https://doi.org/10.1016/0140-6736(92)93158-j
Launay JC, Nespoulos O, Guinet-Lebreton A, Besnard Y, Savourey G (2004) Prevention of acute mountain sickness by low positive end-expiratory pressure in field conditions. Scand J Work Environ Health 30(4):322–326
Leadbetter G, Keyes LE, Maakestad KM, Olson S, Tissot van Patot MC, Hackett PH (2009) Ginkgo biloba does—and does not—prevent acute mountain sickness. Wilderness Environ Med 20(1):66–71. https://doi.org/10.1580/08-WEME-BR-247.1
Lee SY, Li MH, Shi LS, Chu H, Ho CW, Chang TC (2013a) Rhodiola crenulata extract alleviates hypoxic pulmonary edema in rats. Evid Based Complement Alternat Med 2013:718739, 9 p. https://doi.org/10.1155/2013/718739
Lee SY, Shi LS, Chu H, Li MH, Ho CW, Lai FY et al (2013b) Rhodiola crenulata and its bioactive components, salidroside and tyrosol, reverse the hypoxia-induced reduction of plasma-membrane-associated Na, K-ATPase expression via inhibition of ROS-AMPK-PKC ξ pathway. Evid Based Complement Alternat Med 2013:284150. https://doi.org/10.1155/2013/284150
Looney MR, Sartori C, Chakraborty S, James PF, Lingrel JB, Matthay MA (2005) Decreased expression of both the alpha1- and alpha2-subunits of the Na-K-ATPase reduces maximal alveolar epithelial fluid clearance. Am J Phys Lung Cell Mol Phys 289(1):L104–L110
Louajri A, Harraga S, Godot V, Toubin G, Kantelip JP, Magnin P (2001) The effect of Ginkgo biloba extract on free radical production in hypoxic rats. Biol Pharm Bull 24(6):710–712. https://doi.org/10.1248/bpb.24.710
Luks AM, Swenson ER (2008) Medication and dosage considerations in the prophylaxis and treatment of high-altitude illness. Chest 133(3):744–755. https://doi.org/10.1378/chest.07-1417
Luks AM, McIntosh SE, Grissom CK, Auerbach PS, Rodway GW, Schoene RB, Zafren K, Hackett PH (2010) Wilderness Medical Society Consensus Guidelines for the Prevention and Treatment of Acute Altitude Illness. Wilderness Environ Med 21:146–155
Luks AM, McIntosh SE, Grissom CK, Auerbach PS, Rodway GW, Schoene RB et al (2014) Wilderness Medical Society Practice Guidelines for the prevention and treatment of acute altitude illness: 2014 update. Wilderness Environ Med 25(4 Suppl):S4–S14
Luks AM, Swenson ER, Bärtsch P (2017) Acute high-altitude sickness. Eur Respir Rev 26:160096. https://doi.org/10.1183/16000617.0096-2016
Magalhães J, Ascensão A, Viscor G, Soares J, Oliveira J, Marques F, Duarte J (2004) Oxidative stress in humans during and after 4 hours of hypoxia at a simulated altitude of 5500 m. Aviat Space Environ Med 75(1):16–22
Marcocci L, Maguire JJ, Droy-Lefaix MT, Packer L (1994) The nitric oxide-scavenging properties of Ginkgo biloba extract EGb 761. Biochem Biophys Res Commun 201(2):748–755. https://doi.org/10.1006/bbrc.1994.1764
Mazzeo RS, Child A, Butterfield GE, Mawson JT, Zamudio S, Moore LG (1998) Catecholamine response during 12 days of high altitude exposure (4,300 m) in women. J Appl Physiol 84(4):1151–1157
Milledge JS, Cotes PM (1985) Serum erythropoietin in humans at high altitude and its relation to plasma renin. J Appl Physiol 59(2):360–364. https://doi.org/10.1152/jappl.1985.59.2.360
Monge C (1942) Life in the Andes and chronic mountain sickness. Science 95(2456):79–84. https://doi.org/10.1126/science.95.2456.79
Moraga FA, Flores A, Serra J, Esnaola C, Barriento C (2007) Ginkgo biloba decreases acute mountain sickness in people ascending to high altitude at Ollagüe (3696 m) in northern Chile. Wilderness Environ Med 18(4):251–257. https://doi.org/10.1580/06-WEME-OR-062R2.1
Murdoch DR (1996) Acute mountain sickness. J R Soc Med 89(12):728
Naik SR, Pilgaonkar VW, Panda VS (2006) Evaluation of antioxidant activity of Ginkgo biloba phytosomes in rat brain. Phytother Res 20(11):1013–1016. https://doi.org/10.1002/ptr.1976
Packer L, Tritschler HJ, Wessel K (1997) Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic Biol Med 22(1–2):359–378. https://doi.org/10.1016/s0891-5849(96)00269-9
Palmer BF (2010) Physiology and pathophysiology with ascent to altitude. Am J Med Sci 340(1):69–77. https://doi.org/10.1097/MAJ.0b013e3181d3cdbe
Panossian A, Wikman G, Sarris J (2010) Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacy. Phytomedicine 17(7):481–493. https://doi.org/10.1016/j.phymed.2010.02.002
Paralikar SJ, Paralikar JH (2010) High-altitude medicine. Indian J Occup Environ Med 14:6–12. https://doi.org/10.4103/0019-5278.64608. https://www.ijoem.com/text.asp?2010/14/1/6/64608
van Patot MC, Keyes LE, Leadbetter G 3rd, Hackett PH (2009) Ginkgo biloba for prevention of acute mountain sickness: does it work? High Alt Med Biol 10(1):33–43. https://doi.org/10.1089/ham.2008.1085
Pérez-Pinzón MA, Xu GP, Mumford PL, Dietrich WD, Rosenthal M, Sick TJ (1997) Rapid ischemic preconditioning protects rats from cerebral anoxia/ischemia. Adv Exp Med Biol 428:155–161. https://doi.org/10.1007/978-1-4615-5399-1_22
Pfeiffer JM, Askew EW, Roberts DE, Wood SM, Benson JE, Johnson SC, Freedman MS (1999) Effect of antioxidant supplementation on urine and blood markers of oxidative stress during extended moderate-altitude training. Wilderness Environ Med 10(2):66–74. https://doi.org/10.1580/1080-6032(1999)010[0066:eoasou]2.3.co;2
Pialoux V, Mounier R, Brown AD, Steinback CD, Rawling JM, Poulin MJ (2009) Relationship between oxidative stress and HIF-1 alpha mRNA during sustained hypoxia in humans. Free Radic Biol Med 46(2):321–326. https://doi.org/10.1016/j.freeradbiomed.2008.10.047
Pierre S, Jamme I, Droy-Lefaix M-T, Nouvelot A, Maixent J-M (1999) Ginkgo biloba extract (EGb-761) protects Na,K-ATPase activity during cerebral ischemia in mice. Neuroreport 10:47–51
Ren X, Zhang Q, Wang H, Man C, Hong H, Chen L, Li T, Ye P (2015) Effect of intravenous iron supplementation on acute mountain sickness: a preliminary randomized controlled study. Med Sci Monit 15(21):2050–2057. https://doi.org/10.12659/MSM.891182
Roach RC, Hackett PH (2001) Frontiers of hypoxia research: acute mountain sickness. J Exp Biol 204(Pt 18):3161–3170
Roncin JP, Schwartz F, D’Arbigny P (1996) EGb 761 in control of acute mountain sickness and vascular reactivity to cold exposure. Aviat Space Environ Med 67(5):445–452
Salazar H, Swanson J, Mozo K, White AC Jr, Cabada MM (2012) Acute mountain sickness impact among travelers to Cusco. Peru. J Travel Med 19(4):220–225. https://doi.org/10.1111/j.1708-8305.2012.00606.x
Scherrer U, Rexhaj E, Jayet PY, Allemann Y, Sartori C (2010) New insights in the pathogenesis of high-altitude pulmonary edema. Prog Cardiovasc Dis 52(6):485–492. https://doi.org/10.1016/j.pcad.2010.02.004
Schilling L, Wahl M (1999) Mediators of cerebral edema. Adv Exp Med Biol 474:123–141. https://doi.org/10.1007/978-1-4615-4711-2_11
Schmidt MC, Askew EW, Roberts DE, Prior RL, Ensign WY Jr, Hesslink RE Jr (2002) Oxidative stress in humans training in a cold, moderate altitude environment and their response to a phytochemical antioxidant supplement. Wilderness Environ Med 13:94–105
Seupaul RA, Welch JL, Malka ST, Emmett TW (2012) Pharmacologic prophylaxis for acute mountain sickness: a systematic shortcut review. Ann Emerg Med 59:307–317
Stream JO, Grissom CK (2008) Update on high-altitude pulmonary edema: pathogenesis, prevention, and treatment. Wilderness Environ Med 19:293–303
Talbot NP, Smith TG, Privat C, Nickol AH, Rivera-Ch M, León-Velarde F, Dorrington KL, Robbins PA (2011) Intravenous iron supplementation may protect against acute mountain sickness: a randomized, double-blinded, placebo-controlled trial. High Alt Med Biol 12(3):265–269
Tsai TY, Wang SH, Lee YK, Su YC (2018) Ginkgo biloba extract for prevention of acute mountain sickness: a systematic review and meta-analysis of randomised controlled trials. BMJ Open 8(8):e022005. https://doi.org/10.1136/bmjopen-2018-022005
Van Mil AH, Spilt A, Van Buchem MA, Bollen EL, Teppema L, Westendorp RG, Blauw GJ (2002) Nitric oxide mediates hypoxia-induced cerebral vasodilation in humans. J Appl Physiol 92(3):962–966. https://doi.org/10.1152/japplphysiol.00616.2001
Vardy J, Vardy J, Judge K (2005) Can knowledge protect against acute mountain sickness? J Public Health (Oxf) 27(4):366–370. https://doi.org/10.1093/pubmed/fdi060
Vasankari TJ, Kujala UM, Rusko H, Sarna S, Ahotupa M (1997) The effect of endurance exercise at moderate altitude on serum lipid peroxidation and antioxidative functions in humans. Eur J Appl Physiol Occup Physiol 75(5):396–399. https://doi.org/10.1007/s004210050178
Zafren K (2014) Prevention of high altitude illness. Travel Med Infect Dis 12(1):29–39
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Singh, S. (2022). High Altitude Sickness and Antioxidant Interventions. In: Sharma, N.K., Arya, A. (eds) High Altitude Sickness – Solutions from Genomics, Proteomics and Antioxidant Interventions. Springer, Singapore. https://doi.org/10.1007/978-981-19-1008-1_12
Download citation
DOI: https://doi.org/10.1007/978-981-19-1008-1_12
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-19-1007-4
Online ISBN: 978-981-19-1008-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)